1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Japanese year-end approvals include Eliquis, Ryzodeg and Cimzia

 
• By Ian Haydock

Bristol-Myers Squibb's novel anticoagulant Eliquis (apixaban 2.5mg tablet) has been approved in Japan for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation, setting the stage for a market showdown with Bayer's Xarelto (rivaroxaban) and Boehringer Ingelheim's Prazaxa (dabigatran) in this setting.

Bristol-Myers Squibb's novel anticoagulant Eliquis (apixaban 2.5mg tablet) has been approved in Japan for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation, setting the stage for a market showdown with Bayer's Xarelto (rivaroxaban) and Boehringer Ingelheim's Prazaxa (dabigatran) in this setting.

The Japanese regulatory clearance for the BMS oral direct Factor Xa inhibitor comes hot on the heels of the EU...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapeutic Category

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?